![](https://monteverdelaw.com/wp-content/uploads/case-logo/reata-pharmaceuticals-inc.png)
Reata Pharmaceuticals, Inc. (Nasdaq: RETA), relating to its proposed sale to Biogen, Inc. Under the terms of the agreement, RETA shareholders are expected to receive $172.50 in cash per share they own.
Reata Pharmaceuticals, Inc. (Nasdaq: RETA), relating to its proposed sale to Biogen, Inc. Under the terms of the agreement, RETA shareholders are expected to receive $172.50 in cash per share they own.